Treatment of systemic JIA: When do we need a biologic? Real world data of a single center

References

• Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–2.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19:424–30.
   PubMed Web of Science ®Google Scholar
• Kumar S, Kunhiraman DS, Rajam L. Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA). Pediatr Rheumatol. 2012;10(1):40.
   PubMedGoogle Scholar
• Schulert GS, Minoia F, Bohnsack J, Cron RQ, Hashad S, KonÉ-Paut I, et al. Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis. Arthritis Care Res. 2018;70(3):409–19.
   PubMed Web of Science ®Google Scholar
• Kimura Y, Fieldston E, Devries-Vandervlugt B, Li S, Imundo L. High dose, alternate day glucocorticoids for systemic onset juvenile rheumatoid arthritis. J Rheumatol 2000;27:2018–24.
   PubMed Web of Science ®Google Scholar
• Vannucci G, Cantarini L, Giani T, Marrani E, Moretti D, Pagnini I, et al. Glucocorticoids in the management of systemic juvenile idiopathic arthritis. Pediatr Drugs. 2013;15(5):343–9.
   PubMed Web of Science ®Google Scholar
• Xu J, Winkler J, Sabarinath SN, Derendorf H. Assessment of the impact of dosing time on the pharmacokinetics/pharmacodynamics of prednisolone. AAPS J. 2008;10(2):331.
   PubMed Web of Science ®Google Scholar
• Kimura Y, Grevich S, Beukelman T, Morgan E, Nigrovic PA, Mieszkalski K, et al. Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic juvenile idiopathic arthritis consensus treatment plans. Pediatr Rheumatol. 2017;15(1):23.
   PubMedGoogle Scholar
• Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2008;59(12):1796–804.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387(10019):671–8.
   PubMed Web of Science ®Google Scholar
• Bilocca D, Hargadon B, Pavord ID, Green RH, Brightling CE, Bradding P, et al. The role of oral methotrexate as a steroid sparing agent in refractory eosinophilic asthma. Chron Respir Dis. 2018;15(1):85–7.
   PubMed Web of Science ®Google Scholar
• Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005;57(2):163–72.
   PubMed Web of Science ®Google Scholar
• Kaplan-Messas A, Barkana Y, Avni I, Neumann R. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm. 2003;11(2):131–9.
   PubMed Web of Science ®Google Scholar
• Mitre E, Talaat KR, Sperling MR, Nash TE. Methotrexate as a corticosteroid-sparing agent in complicated neurocysticercosis. Clin Infect Dis. 2007;44(4):549–53.
   PubMed Web of Science ®Google Scholar
• Swierkot J, Szechiński J. Methotrexate in rheumatoid arthritis. Pharmacol Rep. 2006;58(4):473: 473–92.
   PubMed Web of Science ®Google Scholar
• Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63(4):465–82.
   PubMed Web of Science ®Google Scholar
• O’Brien CE, Price ET. The blood neutrophil to lymphocyte ratio correlates with clinical status in children with cystic fibrosis: a retrospective study. PLOS One. 2013;8(10):e77420.
   PubMed Web of Science ®Google Scholar
• Kim JY, Park T, Jeong SH, Jeong CY, Ju YT, Lee YJ, et al. Prognostic importance of baseline neutrophil to lymphocyte ratio in patients with advanced papillary thyroid carcinomas. Endocrine. 2014;46(3):526–31.
   PubMed Web of Science ®Google Scholar
• Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol. 2008;102(6):653–7.
   PubMed Web of Science ®Google Scholar
• Uslu AU, Deveci K, Korkmaz S, Aydin B, Senel S, Sancakdar E, et al. Is neutrophil/lymphocyte ratio associated with subclinical inflammation and amyloidosis in patients with familial Mediterranean fever?. Biomed Res Int. 2013;2013:1–5.
   Web of Science ®Google Scholar
• Makay B, Gücenmez OA, Duman M, Unsal E. The relationship of neutrophil-to-lymphocyte ratio with gastrointestinal bleeding in Henoch-Schonlein purpura. Rheumatol Int. 2014;34(9):1323–7.
   PubMed Web of Science ®Google Scholar
• Beukelman T, Xie F, Baddley JW, Chen L, Mannion ML, Saag KG, et al. The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. Arthritis Res Ther. 2016;18(1):210.
   PubMedGoogle Scholar
• Swart JF, de Roock S, Wulffraat NM. What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?. Arthritis Res Ther. 2013;15(3):213.
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cooper K, Harris P, Picot J, Rose M. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2016;20(34):1–222.
   Google Scholar
• Brunelli JB, Schmidt AR, Sallum AME, Goldenstein-Schainberg C, Bonfá E, Silva CA, et al. High rate of serious infection in juvenile idiopathic arthritis patients under biologic therapy in a real-life setting. Mod Rheumatol. 2018;28(2):264–70.
   PubMed Web of Science ®Google Scholar
• Schneider R, Laxer RM. Systemic onset juvenile rheumatoid arthritis. Clin Rheumatol. 1998;12(2):245–71.
   Web of Science ®Google Scholar
• Kimura Y, Pinho P, Walco G, Higgins G, Hummell D, Szer I, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2005;32(5):935–42.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Nakagishi Y, Inoue N, Mizuta M, Yachie A. Leucine-rich α2-glycoprotein as the acute-phase reactant to detect systemic juvenile idiopathic arthritis disease activity during anti-interleukin-6 blockade therapy: a case series. Mod Rheumatol. 2017;27(5):833–7.
   PubMed Web of Science ®Google Scholar
• Wallace C, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31:2290–4.
   PubMed Web of Science ®Google Scholar
• DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, Schneider R, Stoll ML. Consensus treatment plans for new‐onset systemic juvenile idiopathic arthritis. Arthritis Care Res. 2012;64:7–10.
   Web of Science ®Google Scholar
• Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine. 2019;86(3):301–7.
   PubMed Web of Science ®Google Scholar
• Ohta A, Sitkovsky M. Extracellular adenosine-mediated modulation of regulatory T cells. Front Immunol. 2014;5:304.
   PubMed Web of Science ®Google Scholar
• Haskó G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov. 2008;7(9):759–70.
   PubMed Web of Science ®Google Scholar
• Woo P, Southwood TR, Prieur AM, Dore CJ, Grainger J, David J, et al. Randomized, placebo‐controlled, crossover trial of low‐dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000;43(8):1849–57.
   PubMed Web of Science ®Google Scholar
• Rose CD, Singsen BH, Eichenfield AH, Goldsmith DP, Athreya BH. Safety and efficacy of methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr.1990;117(4):653–9.
   PubMed Web of Science ®Google Scholar
• Kotyla P, Batko B, Zuber Z, Almgren-Rachtan A, Chudek J, Kucharz EJ. Effectiveness of subcutaneously administered methotrexate in patients with rheumatoid arthritis. Adv Clin Exp Med. 2019;28(9):1229–35.
   PubMed Web of Science ®Google Scholar
• Alsufyani K, Ortiz-Alvarez O, Cabral DA, Tucker LB, Petty RE, Malleson PN. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J. Rheumatol 2004;31(1):179–82.
   PubMed Web of Science ®Google Scholar
• Żuber Z, Turowska-Heydel D, Sobczyk M, Banach-Górnicka M, Rusnak K, Piszczek A, et al. Methotrexate efficacy and tolerability after switching from oral to subcutaneous route of administration in juvenile idiopathic arthritis. Reumatologia. 2016;1(1):19–23.
   Google Scholar
• Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr.1996;129(5):750–4.
   PubMed Web of Science ®Google Scholar
• Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12(5):259–68.
   PubMed Web of Science ®Google Scholar
• Ravelli A, Caria MC, Buratti S, Malattia C, Temporini F, Martini A. Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2001;28(4):865–7.
   PubMed Web of Science ®Google Scholar
• Dewoolkar M, Cimaz R, Chickermane PR, Khubchandani RP. Course, outcome and complications in children with systemic onset juvenile idiopathic arthritis. Indian J Pediatr. 2017;84(4):294–8.
   PubMed Web of Science ®Google Scholar